When a heart slips into atrial fibrillation, doctors have two broad ways to reset it: an electrical shock delivered under sedation, or a carefully chosen medication that coaxes the rhythm back on its own. Pharmacological cardioversion — sometimes called chemical cardioversion — uses drugs like flecainide, amiodarone, or ibutilide to restore normal sinus rhythm without the need for anesthesia or a defibrillator. For patients whose AFib started within the last 48 hours and who are otherwise hemodynamically stable, medication is often the first option considered, sparing them the risks and recovery time that come with sedation. This distinction matters more than most people realize, especially for older adults and those managing cognitive decline.
Atrial fibrillation is already one of the strongest independent risk factors for stroke and vascular dementia, and how it gets treated — and how quickly — can shape long-term brain health outcomes. A 2025 emergency department registry study found that pharmacological cardioversion succeeded in 76.8% of cases, compared to 94.9% for electrical cardioversion. The electrical approach is more reliable, but the drug-based route avoids sedation entirely, which for an elderly patient with dementia or delirium risk can be a meaningful advantage. This article walks through the specific drugs doctors use, when they choose medication over shock, the pill-in-the-pocket strategy that lets some patients treat episodes at home, and the safety guardrails that make all of this work — or fail.
Table of Contents
- Which Cardioversion Drugs Do Doctors Use Instead of Electrical Shock?
- When Do Doctors Choose Medication Over Electrical Cardioversion?
- The Pill-in-the-Pocket Strategy for Managing AFib Episodes at Home
- Drug Cardioversion vs. Electrical Cardioversion — Weighing the Tradeoffs
- Safety Risks and Contraindications That Change the Calculus
- Amiodarone’s Unique Role in Patients with Structural Heart Disease
- What Dementia Caregivers Should Know Going Forward
- Conclusion
- Frequently Asked Questions
Which Cardioversion Drugs Do Doctors Use Instead of Electrical Shock?
The medications used for pharmacological cardioversion fall into two main categories: Class IC antiarrhythmics and Class III antiarrhythmics. Each has a different mechanism, speed of action, and risk profile, and the choice depends heavily on the patient’s underlying heart structure. Flecainide, a Class IC drug, is one of the fastest actors — an oral dose of 200 to 300 mg can restore normal rhythm in 80 to 90% of patients within one to two hours when afib has been present for less than 48 hours. Propafenone, another Class IC option given at 450 to 600 mg orally, works through a similar mechanism, though flecainide appears to have a slight edge in conversion rates. On the Class III side, ibutilide is given intravenously — 1 mg over 10 minutes for patients weighing more than 60 kilograms — and works relatively quickly, but it carries a 3 to 4% risk of torsades de pointes, a dangerous ventricular arrhythmia that itself requires cardioversion in roughly 1.7% of patients. Because of this, continuous cardiac monitoring for at least four hours after administration is mandatory.
Dofetilide, another Class III agent, converts about 25 to 30% of patients but must be initiated in the hospital due to the risk of QT prolongation. And then there is amiodarone, the workhorse for patients with structural heart disease, which works more slowly — typically 8 to 12 hours — but can be used in situations where the other drugs are too dangerous. One drug worth noting sits outside the US market entirely. Vernakalant, approved in the EU, Iceland, and Norway but not by the FDA, converts 75 to 82% of patients after a single dose with a median conversion time of just 8 to 14 minutes. For European clinicians, it has become an increasingly attractive first-line option. For American patients and their families, it remains unavailable.
When Do Doctors Choose Medication Over Electrical Cardioversion?
The decision between drugs and shock is not arbitrary — it follows a clinical logic rooted in timing, stability, and risk. Pharmacological cardioversion is generally preferred when atrial fibrillation is recent-onset, meaning it started within the last 48 hours, and the patient is hemodynamically stable with adequate blood pressure, no chest pain, and no signs of heart failure. In these cases, medication offers a reasonable chance of success without the logistical and physiological burden of procedural sedation. For a patient in a memory care facility or an older adult already at risk for delirium, avoiding general anesthesia is not a trivial benefit. However, if the patient is hemodynamically unstable — meaning the arrhythmia is causing dangerously low blood pressure, altered consciousness, or acute heart failure — electrical cardioversion becomes the clear priority.
Speed and reliability matter more in those moments than avoiding sedation. Electrical cardioversion is also the fallback when drug therapy fails. A patient who receives flecainide or ibutilide without converting will typically proceed to electrical cardioversion, sometimes during the same hospital visit. There is a subtlety here that matters for dementia caregivers. Sedation carries real cognitive risks for older adults, including post-procedural confusion, falls, and worsening of baseline cognitive impairment. A conversation with the treating cardiologist about whether pharmacological cardioversion is appropriate — and what the specific risks of sedation would be for that patient — is worth having before an emergency forces a rapid decision.
The Pill-in-the-Pocket Strategy for Managing AFib Episodes at Home
For a select group of patients with infrequent paroxysmal atrial fibrillation — episodes that come and go on their own — there is an option that avoids the emergency room altogether. The pill-in-the-pocket approach allows patients to carry a single dose of flecainide or propafenone and self-administer it at the first sign of an AFib episode. A landmark study published in the New England Journal of Medicine found this strategy worked in more than 80% of carefully selected patients. A separate real-world study confirmed that 73% of patients — 199 out of 273 — successfully restored sinus rhythm using this method, and only 11% ultimately needed electrical cardioversion. The appeal is obvious.
Instead of calling an ambulance, waiting in a crowded emergency department, and potentially undergoing sedation, a patient takes a pill at home and waits for the rhythm to correct itself. For someone caring for a spouse with dementia, or for an older adult living alone, this kind of autonomy can be genuinely life-changing. But the strategy is not without guardrails. A 2022 review in JACC: Clinical Electrophysiology found that significant adverse events occurred in approximately 3% of patients using the pill-in-the-pocket approach, including rare instances of 1:1 atrial flutter and symptomatic bradycardia. The first dose must always be taken in a monitored clinical setting — a hospital or outpatient facility with cardiac monitoring — to ensure the patient tolerates the drug safely before being cleared to use it independently. This is not a strategy that should be initiated at home without medical supervision.
Drug Cardioversion vs. Electrical Cardioversion — Weighing the Tradeoffs
The numbers tell a clear story about effectiveness. The 2025 RECUFA-HULA emergency department registry study compared the two approaches head to head: pharmacological cardioversion succeeded in 76.8% of 160 patients, while electrical cardioversion succeeded in 94.9% of 98 patients. Electrical cardioversion is simply more reliable. If the only goal is restoring sinus rhythm as quickly and dependably as possible, the shock wins. But effectiveness is not the only variable in the equation. Electrical cardioversion requires sedation or general anesthesia, which means the patient must be fasting, an anesthesiologist or sedation-trained physician must be present, and recovery time extends well beyond the procedure itself.
For patients with cognitive impairment, the sedation itself introduces risks of delirium, prolonged confusion, and functional decline. Pharmacological cardioversion, by contrast, requires monitoring but not sedation, and the patient remains awake and oriented throughout. The tradeoff comes down to clinical context. For a younger, otherwise healthy patient presenting to the emergency department with new-onset AFib, a loading dose of flecainide may resolve the problem in under two hours with no sedation required. For an 82-year-old with moderate Alzheimer’s disease and a structurally normal heart, avoiding sedation may be worth accepting the slightly lower conversion rate. For an unstable patient of any age, electrical cardioversion is not optional — it is urgent.
Safety Risks and Contraindications That Change the Calculus
Every cardioversion drug carries the paradoxical risk of proarrhythmia — the medication meant to fix an abnormal rhythm can, in certain patients, trigger an even more dangerous one. This is not a theoretical concern. It is the reason patient selection and monitoring protocols exist, and it is the reason some of these drugs cannot be used outside a hospital setting. The most critical contraindication applies to the Class IC drugs, flecainide and propafenone. These medications are strictly prohibited in patients with ischemic heart disease or significant structural heart disease. The reason is stark: in these patients, Class IC drugs have been shown to increase mortality.
This finding, which emerged from the landmark CAST trial in the late 1980s, fundamentally changed how antiarrhythmics are prescribed. If a patient has a history of heart attack, coronary artery disease, or significant heart failure, amiodarone — despite its slower onset and its own long list of side effects — becomes the safer choice because it can be used in the presence of structural disease. Ibutilide presents its own hazard profile. It is contraindicated in patients with existing QT prolongation, hypokalemia, severe left ventricular hypertrophy, or low ejection fraction. The 3 to 4% incidence of torsades de pointes is high enough to demand continuous telemetry monitoring for at least four hours after administration. For patients with dementia who may not be able to reliably report new symptoms like dizziness or palpitations, this monitoring becomes even more important — the clinical team cannot rely on patient self-report alone.
Amiodarone’s Unique Role in Patients with Structural Heart Disease
When other cardioversion drugs are off the table because of underlying cardiac damage, amiodarone steps in as the default. Its IV loading protocol — 150 mg over 10 minutes, followed by 1 mg per minute for 6 hours, then 0.5 mg per minute for 18 hours — reflects just how slowly and carefully this drug must be introduced. Conversion typically takes 8 to 12 hours, which means it is not the right choice when speed is the priority.
What makes amiodarone indispensable, despite its glacial pace and its notorious long-term side effects on the thyroid, lungs, and liver, is that it remains the only widely recommended pharmacological cardioversion agent for patients with structural heart disease. For the substantial population of older adults who have both atrial fibrillation and heart failure or prior myocardial infarction — conditions that often coexist with cognitive decline — amiodarone may be the only drug-based option available. Understanding this narrows the conversation with a cardiologist considerably: if structural heart disease is present, the choice is usually amiodarone or electrical cardioversion, and little else.
What Dementia Caregivers Should Know Going Forward
The intersection of atrial fibrillation management and cognitive health is an area of growing clinical attention. AFib increases stroke risk fivefold, and both the arrhythmia itself and the micro-emboli it can produce have been linked to accelerated cognitive decline and vascular dementia. How AFib is managed — including the choice between pharmacological and electrical cardioversion — is not just a cardiac question. It is a brain health question.
For caregivers and family members navigating these decisions on behalf of someone with dementia, the key is informed conversation with the treating cardiologist. Ask whether pharmacological cardioversion is an option. Ask about the specific risks of sedation for this patient. Ask whether the pill-in-the-pocket strategy could reduce future emergency visits. These are not fringe questions — they are grounded in guideline-level evidence and can meaningfully affect quality of life for both the patient and the people caring for them.
Conclusion
Pharmacological cardioversion gives doctors a genuine alternative to electrical shock for restoring normal heart rhythm, particularly when atrial fibrillation is caught early and the patient is stable. The available drugs — flecainide, propafenone, ibutilide, dofetilide, amiodarone, and in Europe, vernakalant — each occupy a specific niche defined by the patient’s cardiac anatomy, the urgency of the situation, and the tolerance for risk. The pill-in-the-pocket strategy extends this further, allowing selected patients to manage infrequent episodes without an emergency room visit. None of these options is without risk.
Class IC drugs can kill patients with structural heart disease. Ibutilide can trigger the very arrhythmias it is meant to prevent. Amiodarone works when nothing else can, but it works slowly and leaves a trail of organ-level side effects with long-term use. For older adults with cognitive impairment, the added variable of sedation avoidance makes pharmacological cardioversion worth discussing with every AFib diagnosis — not as a replacement for electrical cardioversion, but as a first-line consideration when the clinical picture allows it.
Frequently Asked Questions
What is the fastest-acting cardioversion drug available?
In the United States, flecainide is among the fastest, converting 80 to 90% of recent-onset AFib patients within one to two hours. In Europe, vernakalant works even faster, with a median conversion time of 8 to 14 minutes, but it is not FDA-approved.
Can a patient with dementia use the pill-in-the-pocket strategy?
It depends on the individual. The strategy requires the patient to recognize AFib symptoms and self-administer the medication at the right time. For patients with significant cognitive impairment, a well-trained caregiver could potentially manage this process, but it should be discussed thoroughly with the cardiologist and first tested in a monitored setting.
Is pharmacological cardioversion safer than electrical cardioversion?
Not necessarily safer overall — it avoids the risks of sedation but introduces the risk of proarrhythmia, where the drug itself triggers a dangerous heart rhythm. The safety comparison depends entirely on the individual patient’s cardiac history, current stability, and tolerance for anesthesia.
Why can’t flecainide be used in all AFib patients?
Flecainide is contraindicated in patients with ischemic heart disease or significant structural heart disease because it has been shown to increase mortality in these populations. Amiodarone is the typical alternative for these patients.
How long does amiodarone take to convert AFib?
Amiodarone typically requires 8 to 12 hours to restore sinus rhythm when given intravenously. Its loading protocol involves three stages over 24 hours: 150 mg over 10 minutes, then 1 mg per minute for 6 hours, then 0.5 mg per minute for 18 hours.
What happens if pharmacological cardioversion fails?
If drug therapy does not restore normal rhythm, doctors typically proceed to electrical cardioversion, often during the same hospital visit. Electrical cardioversion has a success rate of approximately 95% and serves as the reliable backup when medications fall short.
